Compile Data Set for Download or QSAR
Report error Found 117 Enz. Inhib. hit(s) with all data for entry = 3455
TargetSerine/threonine-protein kinase mTOR(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM400818(QL-XII-03 | US10000483, Compound II-11)
Affinity DataIC50: 1nMAssay Description:DiscoverX binding assays were performed according to published methods (Fabian et al., Nat. Biotechnol. 23, 329-36 (2005); Davis et al., Nat. Biotech...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM400813(QL-X-138 | US10000483, Compound II-6)
Affinity DataIC50: 5nMAssay Description:DiscoverX binding assays were performed according to published methods (Fabian et al., Nat. Biotechnol. 23, 329-36 (2005); Davis et al., Nat. Biotech...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetCytoplasmic tyrosine-protein kinase BMX(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM400819(QL-XII-44 | US10000483, Compound II-12)
Affinity DataIC50: 5.62nMAssay Description:Purified BMX was mixed with substrate (FAK or Bmxtides), kinase buffer (final 20 mM HEPES, pH 7.5, 10 mM MgCl2, 20 mM β-glycerophosphate, 1 mM d...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM400820(QL-XII-45 | US10000483, Compound II-13)
Affinity DataIC50: 6nMAssay Description:DiscoverX binding assays were performed according to published methods (Fabian et al., Nat. Biotechnol. 23, 329-36 (2005); Davis et al., Nat. Biotech...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetCytoplasmic tyrosine-protein kinase BMX(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM400819(QL-XII-44 | US10000483, Compound II-12)
Affinity DataIC50: 6nMAssay Description:DiscoverX binding assays were performed according to published methods (Fabian et al., Nat. Biotechnol. 23, 329-36 (2005); Davis et al., Nat. Biotech...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetCytoplasmic tyrosine-protein kinase BMX(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM50245587(CHEMBL4077064 | US10000483, Compound II-4)
Affinity DataIC50: 6.73nMAssay Description:Purified BMX was mixed with substrate (FAK or Bmxtides), kinase buffer (final 20 mM HEPES, pH 7.5, 10 mM MgCl2, 20 mM β-glycerophosphate, 1 mM d...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetCytoplasmic tyrosine-protein kinase BMX(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM400813(QL-X-138 | US10000483, Compound II-6)
Affinity DataIC50: 7nMAssay Description:DiscoverX binding assays were performed according to published methods (Fabian et al., Nat. Biotechnol. 23, 329-36 (2005); Davis et al., Nat. Biotech...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM400819(QL-XII-44 | US10000483, Compound II-12)
Affinity DataIC50: 7nMAssay Description:DiscoverX binding assays were performed according to published methods (Fabian et al., Nat. Biotechnol. 23, 329-36 (2005); Davis et al., Nat. Biotech...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM50245587(CHEMBL4077064 | US10000483, Compound II-4)
Affinity DataIC50: 7nMAssay Description:DiscoverX binding assays were performed according to published methods (Fabian et al., Nat. Biotechnol. 23, 329-36 (2005); Davis et al., Nat. Biotech...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetCytoplasmic tyrosine-protein kinase BMX(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM50245587(CHEMBL4077064 | US10000483, Compound II-4)
Affinity DataIC50: 7nMAssay Description:DiscoverX binding assays were performed according to published methods (Fabian et al., Nat. Biotechnol. 23, 329-36 (2005); Davis et al., Nat. Biotech...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetCytoplasmic tyrosine-protein kinase BMX(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM400813(QL-X-138 | US10000483, Compound II-6)
Affinity DataIC50: 7.36nMAssay Description:Purified BMX was mixed with substrate (FAK or Bmxtides), kinase buffer (final 20 mM HEPES, pH 7.5, 10 mM MgCl2, 20 mM β-glycerophosphate, 1 mM d...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetCytoplasmic tyrosine-protein kinase BMX(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM102620(N-[5-[9-[4-(methanesulfonamido)phenyl]-2-oxobenzo[...)
Affinity DataIC50: 7.99nMAssay Description:Purified BMX was mixed with substrate (FAK or Bmxtides), kinase buffer (final 20 mM HEPES, pH 7.5, 10 mM MgCl2, 20 mM β-glycerophosphate, 1 mM d...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetCytoplasmic tyrosine-protein kinase BMX(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM102620(N-[5-[9-[4-(methanesulfonamido)phenyl]-2-oxobenzo[...)
Affinity DataIC50: 8nMAssay Description:DiscoverX binding assays were performed according to published methods (Fabian et al., Nat. Biotechnol. 23, 329-36 (2005); Davis et al., Nat. Biotech...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetCytoplasmic tyrosine-protein kinase BMX(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM400810(QL-XII-56 | US10000483, Compound II-3)
Affinity DataIC50: 8nMAssay Description:DiscoverX binding assays were performed according to published methods (Fabian et al., Nat. Biotechnol. 23, 329-36 (2005); Davis et al., Nat. Biotech...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetCytoplasmic tyrosine-protein kinase BMX(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM400810(QL-XII-56 | US10000483, Compound II-3)
Affinity DataIC50: 8.16nMAssay Description:Purified BMX was mixed with substrate (FAK or Bmxtides), kinase buffer (final 20 mM HEPES, pH 7.5, 10 mM MgCl2, 20 mM β-glycerophosphate, 1 mM d...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetCytoplasmic tyrosine-protein kinase BMX(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM400821(QL-XII-46 | US10000483, Compound II-14)
Affinity DataIC50: 8.75nMAssay Description:Purified BMX was mixed with substrate (FAK or Bmxtides), kinase buffer (final 20 mM HEPES, pH 7.5, 10 mM MgCl2, 20 mM β-glycerophosphate, 1 mM d...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetCytoplasmic tyrosine-protein kinase BMX(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM400821(QL-XII-46 | US10000483, Compound II-14)
Affinity DataIC50: 9nMAssay Description:DiscoverX binding assays were performed according to published methods (Fabian et al., Nat. Biotechnol. 23, 329-36 (2005); Davis et al., Nat. Biotech...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetCytoplasmic tyrosine-protein kinase BMX(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM400815(QL-XI-13 | US10000483, Compound II-8)
Affinity DataIC50: 10.5nMAssay Description:Purified BMX was mixed with substrate (FAK or Bmxtides), kinase buffer (final 20 mM HEPES, pH 7.5, 10 mM MgCl2, 20 mM β-glycerophosphate, 1 mM d...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetCytoplasmic tyrosine-protein kinase BMX(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM400815(QL-XI-13 | US10000483, Compound II-8)
Affinity DataIC50: 11nMAssay Description:DiscoverX binding assays were performed according to published methods (Fabian et al., Nat. Biotechnol. 23, 329-36 (2005); Davis et al., Nat. Biotech...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM400802(QL-XII-51 | US10000483, Compound I-11)
Affinity DataIC50: 11nMAssay Description:DiscoverX binding assays were performed according to published methods (Fabian et al., Nat. Biotechnol. 23, 329-36 (2005); Davis et al., Nat. Biotech...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetCytoplasmic tyrosine-protein kinase BMX(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM400817(QL-XI-76 | US10000483, Compound II-10)
Affinity DataIC50: 12nMAssay Description:DiscoverX binding assays were performed according to published methods (Fabian et al., Nat. Biotechnol. 23, 329-36 (2005); Davis et al., Nat. Biotech...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM400821(QL-XII-46 | US10000483, Compound II-14)
Affinity DataIC50: 12nMAssay Description:DiscoverX binding assays were performed according to published methods (Fabian et al., Nat. Biotechnol. 23, 329-36 (2005); Davis et al., Nat. Biotech...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetCytoplasmic tyrosine-protein kinase BMX(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM400817(QL-XI-76 | US10000483, Compound II-10)
Affinity DataIC50: 12.1nMAssay Description:Purified BMX was mixed with substrate (FAK or Bmxtides), kinase buffer (final 20 mM HEPES, pH 7.5, 10 mM MgCl2, 20 mM β-glycerophosphate, 1 mM d...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetCytoplasmic tyrosine-protein kinase BMX(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM400812(QL-X-134 | US10000483, Compound II-5)
Affinity DataIC50: 12.9nMAssay Description:Purified BMX was mixed with substrate (FAK or Bmxtides), kinase buffer (final 20 mM HEPES, pH 7.5, 10 mM MgCl2, 20 mM β-glycerophosphate, 1 mM d...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetCytoplasmic tyrosine-protein kinase BMX(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM400809(QL-XII-115 | US10000483, Compound I-18)
Affinity DataIC50: 13nMAssay Description:DiscoverX binding assays were performed according to published methods (Fabian et al., Nat. Biotechnol. 23, 329-36 (2005); Davis et al., Nat. Biotech...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetCytoplasmic tyrosine-protein kinase BMX(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM400820(QL-XII-45 | US10000483, Compound II-13)
Affinity DataIC50: 13nMAssay Description:DiscoverX binding assays were performed according to published methods (Fabian et al., Nat. Biotechnol. 23, 329-36 (2005); Davis et al., Nat. Biotech...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetCytoplasmic tyrosine-protein kinase BMX(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM400812(QL-X-134 | US10000483, Compound II-5)
Affinity DataIC50: 13nMAssay Description:DiscoverX binding assays were performed according to published methods (Fabian et al., Nat. Biotechnol. 23, 329-36 (2005); Davis et al., Nat. Biotech...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetCytoplasmic tyrosine-protein kinase BMX(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM400809(QL-XII-115 | US10000483, Compound I-18)
Affinity DataIC50: 13.3nMAssay Description:Purified BMX was mixed with substrate (FAK or Bmxtides), kinase buffer (final 20 mM HEPES, pH 7.5, 10 mM MgCl2, 20 mM β-glycerophosphate, 1 mM d...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetCytoplasmic tyrosine-protein kinase BMX(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM400820(QL-XII-45 | US10000483, Compound II-13)
Affinity DataIC50: 13.3nMAssay Description:Purified BMX was mixed with substrate (FAK or Bmxtides), kinase buffer (final 20 mM HEPES, pH 7.5, 10 mM MgCl2, 20 mM β-glycerophosphate, 1 mM d...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM400810(QL-XII-56 | US10000483, Compound II-3)
Affinity DataIC50: 14nMAssay Description:DiscoverX binding assays were performed according to published methods (Fabian et al., Nat. Biotechnol. 23, 329-36 (2005); Davis et al., Nat. Biotech...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetCytoplasmic tyrosine-protein kinase BMX(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM400814(QL-X-132 | US10000483, Compound II-7)
Affinity DataIC50: 15.7nMAssay Description:Purified BMX was mixed with substrate (FAK or Bmxtides), kinase buffer (final 20 mM HEPES, pH 7.5, 10 mM MgCl2, 20 mM β-glycerophosphate, 1 mM d...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetCytoplasmic tyrosine-protein kinase BMX(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM400799(QL-XI-77 | US10000483, Compound I-7)
Affinity DataIC50: 15.9nMAssay Description:Purified BMX was mixed with substrate (FAK or Bmxtides), kinase buffer (final 20 mM HEPES, pH 7.5, 10 mM MgCl2, 20 mM β-glycerophosphate, 1 mM d...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM400809(QL-XII-115 | US10000483, Compound I-18)
Affinity DataIC50: 16nMAssay Description:DiscoverX binding assays were performed according to published methods (Fabian et al., Nat. Biotechnol. 23, 329-36 (2005); Davis et al., Nat. Biotech...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetCytoplasmic tyrosine-protein kinase BMX(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM400799(QL-XI-77 | US10000483, Compound I-7)
Affinity DataIC50: 16nMAssay Description:DiscoverX binding assays were performed according to published methods (Fabian et al., Nat. Biotechnol. 23, 329-36 (2005); Davis et al., Nat. Biotech...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM400812(QL-X-134 | US10000483, Compound II-5)
Affinity DataIC50: 16nMAssay Description:DiscoverX binding assays were performed according to published methods (Fabian et al., Nat. Biotechnol. 23, 329-36 (2005); Davis et al., Nat. Biotech...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetCytoplasmic tyrosine-protein kinase BMX(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM400814(QL-X-132 | US10000483, Compound II-7)
Affinity DataIC50: 16nMAssay Description:DiscoverX binding assays were performed according to published methods (Fabian et al., Nat. Biotechnol. 23, 329-36 (2005); Davis et al., Nat. Biotech...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM400817(QL-XI-76 | US10000483, Compound II-10)
Affinity DataIC50: 17nMAssay Description:DiscoverX binding assays were performed according to published methods (Fabian et al., Nat. Biotechnol. 23, 329-36 (2005); Davis et al., Nat. Biotech...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetSerine/threonine-protein kinase mTOR(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM400812(QL-X-134 | US10000483, Compound II-5)
Affinity DataIC50: 17nMAssay Description:DiscoverX binding assays were performed according to published methods (Fabian et al., Nat. Biotechnol. 23, 329-36 (2005); Davis et al., Nat. Biotech...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetCytoplasmic tyrosine-protein kinase BMX(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM400802(QL-XII-51 | US10000483, Compound I-11)
Affinity DataIC50: 18nMAssay Description:DiscoverX binding assays were performed according to published methods (Fabian et al., Nat. Biotechnol. 23, 329-36 (2005); Davis et al., Nat. Biotech...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM400815(QL-XI-13 | US10000483, Compound II-8)
Affinity DataIC50: 18nMAssay Description:DiscoverX binding assays were performed according to published methods (Fabian et al., Nat. Biotechnol. 23, 329-36 (2005); Davis et al., Nat. Biotech...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetCytoplasmic tyrosine-protein kinase BMX(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM400802(QL-XII-51 | US10000483, Compound I-11)
Affinity DataIC50: 18.1nMAssay Description:Purified BMX was mixed with substrate (FAK or Bmxtides), kinase buffer (final 20 mM HEPES, pH 7.5, 10 mM MgCl2, 20 mM β-glycerophosphate, 1 mM d...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetCytoplasmic tyrosine-protein kinase BMX(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM400804(QL-XII-58 | US10000483, Compound I-13)
Affinity DataIC50: 18.1nMAssay Description:Purified BMX was mixed with substrate (FAK or Bmxtides), kinase buffer (final 20 mM HEPES, pH 7.5, 10 mM MgCl2, 20 mM β-glycerophosphate, 1 mM d...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetCytoplasmic tyrosine-protein kinase BMX(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM400822(QL-XII-54 | US10000483, Compound II-16)
Affinity DataIC50: 18.5nMAssay Description:Purified BMX was mixed with substrate (FAK or Bmxtides), kinase buffer (final 20 mM HEPES, pH 7.5, 10 mM MgCl2, 20 mM β-glycerophosphate, 1 mM d...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetSerine/threonine-protein kinase mTOR(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM400814(QL-X-132 | US10000483, Compound II-7)
Affinity DataIC50: 19nMAssay Description:DiscoverX binding assays were performed according to published methods (Fabian et al., Nat. Biotechnol. 23, 329-36 (2005); Davis et al., Nat. Biotech...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetCytoplasmic tyrosine-protein kinase BMX(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM400822(QL-XII-54 | US10000483, Compound II-16)
Affinity DataIC50: 19nMAssay Description:DiscoverX binding assays were performed according to published methods (Fabian et al., Nat. Biotechnol. 23, 329-36 (2005); Davis et al., Nat. Biotech...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM400814(QL-X-132 | US10000483, Compound II-7)
Affinity DataIC50: 19nMAssay Description:DiscoverX binding assays were performed according to published methods (Fabian et al., Nat. Biotechnol. 23, 329-36 (2005); Davis et al., Nat. Biotech...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetCytoplasmic tyrosine-protein kinase BMX(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM400816(QL-XI-75 | US10000483, Compound II-9)
Affinity DataIC50: 19.7nMAssay Description:Purified BMX was mixed with substrate (FAK or Bmxtides), kinase buffer (final 20 mM HEPES, pH 7.5, 10 mM MgCl2, 20 mM β-glycerophosphate, 1 mM d...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetCytoplasmic tyrosine-protein kinase BMX(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM400816(QL-XI-75 | US10000483, Compound II-9)
Affinity DataIC50: 20nMAssay Description:DiscoverX binding assays were performed according to published methods (Fabian et al., Nat. Biotechnol. 23, 329-36 (2005); Davis et al., Nat. Biotech...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetSerine/threonine-protein kinase mTOR(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM400813(QL-X-138 | US10000483, Compound II-6)
Affinity DataIC50: 22nMAssay Description:DiscoverX binding assays were performed according to published methods (Fabian et al., Nat. Biotechnol. 23, 329-36 (2005); Davis et al., Nat. Biotech...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM400799(QL-XI-77 | US10000483, Compound I-7)
Affinity DataIC50: 25nMAssay Description:DiscoverX binding assays were performed according to published methods (Fabian et al., Nat. Biotechnol. 23, 329-36 (2005); Davis et al., Nat. Biotech...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

Displayed 1 to 50 (of 117 total ) | Next | Last >>
Jump to: